Joe Schroers-Martin, MD
@schroersmartin
Followers
438
Following
242
Media
10
Statuses
160
Assistant Professor @StanfordMed @StanfordCancer | Lymphoma genomics, viromics, ctDNA | Former @UHMed @StanfordMedRes
Palo Alto, CA
Joined August 2018
Presenting an overview with Ranjana Advani of the current role of brentuximab and the checkpoint inhibitors in classic Hodgkin lymphoma: https://t.co/S41rWnAZcx Thanks to @JCOOP_ASCO for a great review & publication process.
ascopubs.org
Classic Hodgkin lymphoma (cHL) is highly curable at all stages. Research efforts over the past few decades have largely focused on interim PET-adapted strategies for therapy de-escalation or intens...
0
3
17
At a full capacity #ASH24 session on "Moving the Needle in Hodgkin Lymphoma" - please take a look at our education chapter on the current role of BV!
ashpublications.org
Abstract. The CD30-directed antibody-drug conjugate brentuximab vedotin (BV) was FDA approved in 2011 for the treatment of relapsed classic Hodgkin lymphom
0
0
3
Excited to discuss cell-free DNA in post-transplant lymphomas in the Sunday session on the lymphoma TME and immunology, an ongoing multicenter collaboration with @AshAlizadeh @KiranKhush1 :
0
0
10
Interim PET/CT based strategies have allowed personalized treatment of classic Hodgkin lymphoma. What are the next steps for response adapted therapy in the era of immunotherapies and ctDNA? A review of novel agent approaches and emerging technologies. https://t.co/ZJ9NyfeUJK
0
3
11
⏰ 2 Weeks Until #llmcongress2024 Begins. ⏰ The Lymphoma, Leukemia & Myeloma Congress is fast approaching. With the rise in blood cancer diagnoses, our mission to combat these challenges has never been more crucial. For 24 years, The Lymphoma, Leukemia & Myeloma Congress has
2
0
4
Wow, what? A picture is worth 1000, etc.
0
2
8
A call to solid organ transplant centers! Does anyone have banked plasma samples from transplant patients who have subsequently developed PTLD (pre-diagnosis samples)? Please LMK- we’d love to collaborate for an NIH grant! @AshAlizadeh @schroersmartin @ISHLT @amjtransplant
2
8
24
Monumental effort by GLOW team in publishing the largest analysis of NLPHL to date and answering many key questions about age specific risks, the prognostic impact of variant patterns, and developing a new LP-IPS: https://t.co/kuGpmIMEsh
@glow_nlphl @JCO_ASCO @JamieFlerlage
ascopubs.org
PURPOSENodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and...
0
18
50
Excited to share our work on bispecific immunotherapy modeling with #lymphoma #organoids
We're back with more #organoids! A team at @Stanford and @UCIrvine generated patient-derived #lymphoma organoids to study the tumor microenvironment. @Jkastens_phd @schroersmartin @lisa_wagar @AshAlizadeh 🔖 @CellStemCell: https://t.co/paspaEnLXE 💬: https://t.co/XRDqAciMDW
1
3
15
We're back with more #organoids! A team at @Stanford and @UCIrvine generated patient-derived #lymphoma organoids to study the tumor microenvironment. @Jkastens_phd @schroersmartin @lisa_wagar @AshAlizadeh 🔖 @CellStemCell: https://t.co/paspaEnLXE 💬: https://t.co/XRDqAciMDW
0
1
7
Very excited to share our new study measuring clinical specificity of #immunoglobulin based high-throughput sequencing #IgHTS for #MRD measurement in mature B-cell #lymphomas. #lymsm
https://t.co/4di4t7HVpp
ashpublications.org
TO THE EDITOR:
3
8
61
Impressive data from our first year fellow @ev_lando showing the impact of preemptive rituximab in prevention of PTLD in solid organ transplant recipients. Very large sample! @jenamengual
1
5
20
I have had some amazing mentors, sponsors, and role models in my life and am so grateful for each of them. Big thank you to @BiostatGirl for being a wonderful part of my life and mentoring and supporting me. She taught @hemepa_c @ComeBommier and me so much about PROs! #ASH23
3
9
64
Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today @Nature. #lymsm 1/15 https://t.co/FOBvWSu5Je PDF link at bottom of this thread
nature.com
Nature - The potential use of circulating tumour DNA in classic Hodgkin lymphoma detection, classification and monitoring is defined.
20
79
219
This is a really important analysis in an area of a BIG unmet need (ie, biology in older #HL pts, etc). Surprised this is not an oral presentation. Interesting findings re: EBV and ctDNA. Look forward to the poster & ultimate manuscript. #ASH23 #ASHKudos #GeriOnc #GeriHem
Abstract#4369 Rossi et al, Distinct Circulating Genomic Features of Classical #Hodgkin Lymphoma of #Older Adults #Elderly #cHL #ctDNA #EBV #PhasED-Seq @LysaLymphoma #CedricRossi @nonoscherlebeck
https://t.co/TNvAllXe0h
https://t.co/lDrT0AHbNL
0
2
6
@schroersmartin rocking the podium at #ASH23 with his multimodal studies of #FL #ctDNA including transformation
1
5
35
Abstract #245 Mutter et al, Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification #EPIC-Seq #DoubleHit #DZSig #MachineLearning
@JurikMutter @schroersmartin @mohamshah @max_diehn
https://t.co/M8wod7e9Dz
https://t.co/ssKb08l5rF
1
4
5
Abstract #528 Schroers-Martin et al, Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma #FL #PhasED-Seq #CAPP-Seq #EPIC-Seq #ctDNA #transformation
@schroersmartin @max_diehn
https://t.co/K29KYyM7Fe
https://t.co/JWAKIlrD7K
1
4
5